Impact of Heart Failure Severity on Vutrisiran Efficacy in Transthyretin Amyloidosis With Cardiomyopathy
Vutrisiran demonstrated evidence of benefit across the range of baseline disease severities in HELIOS-B, with the greatest benefit in earlier, less severe disease. (A Study to Evaluate Vutrisiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy [HELIOS-B]; NCT04153149).
Authors
- Ronald Witteles (ORCID: https://orcid.org/0000-0002-3043-1472)
- Emre Aldinc (ORCID: https://orcid.org/0000-0002-7237-4760)
- Daniel Rodriguez Duque (ORCID: https://orcid.org/0000-0002-7270-2787)
- Farooq H. Sheikh (ORCID: https://orcid.org/0000-0001-9687-9475)
- Julian D. Gillmore (ORCID: https://orcid.org/0000-0001-6174-9232)
- Matthew J. Maurer (ORCID: https://orcid.org/0000-0002-1867-0526)
- Pablo García‐Pavía (ORCID: https://orcid.org/0000-0002-5470-2257)
- Caroline Morbach (ORCID: https://orcid.org/0000-0002-0920-6094)
- Satish A. Eraly
Institutions
- Alnylam Pharmaceuticals (United States) (US)
- Georgetown University (US)
- Columbia University Irving Medical Center (US)
- The Royal Free Hospital (GB)
- Hospital Universitario Puerta de Hierro Majadahonda (ES)
- Amyloidosis Foundation (US)
- Universitätsklinikum Würzburg (DE)
- Stanford Medicine (US)
- MedStar Heart & Vascular Institute (US)
- University College London (GB)
- Stanford University (US)
Publication Details
- Journal
- Journal of the American College of Cardiology
- Published
- 2025-03-17
- DOI
- https://doi.org/10.1016/j.jacc.2025.03.477
- Citations
- 7
- Primary Topic
- Amyloidosis: Diagnosis, Treatment, Outcomes
- Type
- article
- Field-Weighted Citation Impact
- 5.64
Funders
- Alnylam Pharmaceuticals